DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA Holdings Inc. (“IQVIA”) (NYSE: IQV) announced today the launch of
an underwritten, secondary public offering of 10,000,000 shares of its
common stock by certain of its existing stockholders, including
affiliates of TPG Global, LLC, CPP Investment Board Private Holdings,
Inc., investment funds associated with Bain Capital Investors, LLC, and
Leonard Green & Partners, L.P. (the “Selling Stockholders”), of which
IQVIA intends to repurchase from the underwriter 2,500,000 shares (the
“Repurchase”). The Repurchase will be completed outside IQVIA’s existing
share repurchase program, under which IQVIA has approximately $195
million of remaining availability.
IQVIA is not offering any stock in this transaction and will not receive
any proceeds from the sale of the shares by the Selling Stockholders in
the offering. IQVIA’s per-share purchase price for the repurchased
shares will be the same as the per-share purchase price payable by the
underwriter to the Selling Stockholders. IQVIA expects to fund the
Repurchase with cash on hand and borrowings from its revolving credit
facility. The Repurchase is subject to completion of the offering and
the satisfaction of other customary conditions.
Morgan Stanley is acting as the sole underwriter of the offering. Morgan
Stanley proposes to offer the shares of IQVIA common stock from time to
time in one or more transactions on the New York Stock Exchange, in the
over-the-counter market or through negotiated transactions at market
prices or at negotiated prices.
An automatic shelf registration statement (including a prospectus)
relating to the offering of common stock was filed with the Securities
and Exchange Commission (“SEC”) on May 24, 2017 and became effective
upon filing. Before you invest, you should read the registration
statement, prospectus, preliminary prospectus supplement and other
documents IQVIA has made available with the SEC for information about
IQVIA and the offering. You may obtain these documents free of charge by
visiting EDGAR on the SEC website at www.sec.gov.
Alternatively, copies of the prospectus and accompanying prospectus
supplement, when available, may be obtained from: Morgan Stanley & Co.
LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New
York, NY 10014.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such an offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or other jurisdiction.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of information, innovative
technology solutions and contract research services focused on using
data and science to help healthcare clients find better solutions for
their patients. Formed through the merger of IMS Health and Quintiles,
IQVIA offers a broad range of solutions that harness advances in
healthcare information, technology, analytics and human ingenuity to
drive healthcare forward. IQVIA enables companies to rethink approaches
to clinical development and commercialization, innovate with confidence
as well as accelerate meaningful healthcare outcomes. IQVIA has
approximately 55,000 employees in more than 100 countries, all committed
to making the potential of human data science a reality. IQVIA’s
approach to human data science is powered by the IQVIA CORE™, driving
unique actionable insights at the intersection of big data,
transformative technology and analytics with extensive domain expertise.
IQVIA’s insights and execution capabilities help biotech, medical
device, and pharmaceutical companies, medical researchers, government
agencies, payers and other healthcare stakeholders tap into a deeper
understanding of diseases, human behaviors and scientific advances, in
an effort to advance their path toward cures.
IQVIAFIN